Imiglucerase
![Subject: Zavesca (Miglustat) [Gaucher Disease] Original Effective Date: 8/22/16](http://data.docslib.org/img/264x/446f445602c9e9fe9cdf5742c1040818.webp)
Top View
- Switching from Imiglucerase to Miglustat for the Treatment of French Patients with Gaucher Disease Type 1
- Brand Generic Guide
- Interstitial Lung Disease in Lysosomal Storage Disorders
- Characterization of Gene-Activated Human Acid-Β-Glucosidase: Crystal Structure, Glycan Composition, and Internalization Into Macrophages
- For Peer Review Only - Page 1 of 59 BMJ Open
- Prior Authorization for Medications
- Essential List of Medicinal Products for Rare Diseases: Recommendations from the Irdirc Rare Disease Treatment Access Working Group William A
- Orphan Drug Designation List
- Eliglustat (Cerdelga®) EOCCO POLICY Policy Type: PA/SP Pharmacy Coverage Policy: EOCCO135
- 5.01.576 Drugs for Rare Diseases
- Cerdelga Eliglustat Molina Clinical Policy
- Genzyme Cerezyme (Imiglucerase for Injection) PROPOSED TEXT of the LABELING of the DRUG
- TITLE: Eliglustat Tartrate, Miglustat, Imiglucerase, Velaglucerase Or A
- Presentation
- Cerezyme Page: 1 of 5
- Imiglucerase
- Velaglucerase Alfa in the Treatment of Gaucher Disease Type 1
- Eric Crombez, M.D